A key decision by the bankruptcy judge could help with protecting consumer data, write Diane Lourdes Dick and Anya Prince.

The rival bid from the 23andMe co-founder and former CEO at one point drew interest from a Fortune 500 company with more than ...

The founder of 23andMe has asked a federal bankruptcy court judge to reopen an auction for the genetic testing company, ...

Nice 23andMe sale hearing ya got there — shame if something happened to it, say attorneys for co-founder and former CEO who ...

Human genetics testing firm 23andMe announced Tuesday it will voluntarily delist from the Nasdaq and deregister with the U.S.

The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

There is nothing more inherently unique and personal to an individual than his or her DNA. Unlike many other types of personal information, a ...

Regeneron will acquire 23andMe’s core assets for $256 million, ensuring customer data privacy and continuing the mission of ...

On 23 March 2025, the direct-to-consumer genetic testing company 23andMe filed a voluntary Chapter 11 petition in a US bankruptcy court.1 The objective of this bankruptcy is to sell the company ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...